Shao SC, Chang KC, Lin SJ, et al. - Different hHF (hospitalization for heart failure) risks among sodium-glucose cotransporter 2 inhibitors were evident in relation to a history of established atherosclerotic cardiovascular diseases (ASCVD). In clinical practice, a more favorable hHF reduction effect may be achieved with the use of dapagliflozin vs empagliflozin in type 2 diabetes (T2D) patients without ASCVD.

• A retrospective multi-institutional cohort study in Taiwan, including 9,586 dapagliflozin new users and 9,586 matched empagliflozin new users among T2D patients.

• Similar overall hHF risks were revealed for dapagliflozin and empagliflozin (HR, hazard ratio: 0.90).

• Only in the subgroup without ASCVD, there were differential hHF risks between dapagliflozin and empagliflozin (HR: 0.67); this was not true for subgroup with ASCVD (HR: 1.12).